Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
STAU1 CRISPR/Cas9 KO Plasmid (m): sc-423181
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- STAU1 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the STAU1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: STAU1 Antibody (C-4): sc-390820
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
STAU1 CRISPR/Cas9 KO Plasmid (m) | sc-423181 | 20 µg | $397.00 |
Overview
Mouse Stau1 encodes STAU1, a double-stranded RNA-binding protein that mediates Staufen-dependent mRNA decay and regulates mRNA localization, stability, and translation. STAU1 participates in post-transcriptional gene control through ribonucleoprotein complex assembly, coupling RNA surveillance with processes such as stress granule dynamics and cytoskeletal transport. In mammalian cells, altered STAU1 activity has been linked to dysregulated RNA metabolism affecting neuronal function and muscle homeostasis, making it relevant for studies of neurodegeneration and neuromuscular phenotypes. As a node in RNA regulatory networks, STAU1 provides a tractable entry point for dissecting how mRNA fate decisions shape cell state and proteome output.
STAU1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Stau1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Stau1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Stau1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish STAU1 protein expression.
This CRISPR knockout system enables efficient generation of Stau1-deficient cell models for investigation of STAU1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Stau1 exon(s) critical for STAU1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Stau1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by STAU1 CRISPR/Cas9 KO Plasmid (m) and STAU1 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Stau1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by STAU1 HDR Plasmid (m) and STAU1 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Stau1 homology arms to support homology-directed repair at defined Stau1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.